← All trials
NCT00386529
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2006
- Primary completion
- Jan 1, 2007
- Completion date
- Aug 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 191
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Inje UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Yeungnam UniversityOverall official - principal investigator
- Inje UniversityCollaborator
- Yonsei UniversityCollaborator
- Keimyung UniversityCollaborator
- Yeungnam UniversityCollaborator
- Seoul National UniversityCollaborator
- Catholic University of KoreaOverall official - principal investigator
- Catholic University of KoreaCollaborator
- Keimyung UniversityOverall official - principal investigator
- Kyungpook UniversityStudy chair
- Kyungpook UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.